Stock price when the opinion was issued
He owns a small holding. Likes their growth profile from their weight-loss drug; they will continue to take market share from Novo Nordisk. The big news this week was that drug shortages were over. They lowered the price too. But shares are expensive at 20x PE on 2028 numbers--expensive for a pharmaceutical. It's had a big run, so he's not adding shares, but trimming.
Like TJX, their momentum is not unwinding, and shares will push to new all-time highs. It's on a streak now, of 7 straight days, that we haven't seen in 2 years.